Press release: Uppsala, November 19, 2018: The Board of Senzime AB (publ) has today appointed Pia Renaudin as new Chief Executive Officer. Pia will start her new position in the first quarter of 2019, and will succeed the current CEO, Lena Söderström, who leaves Senzime after nearly six years. Catrin Molund, Director Marketing & Business Development at Senzime, will assume the role of acting CEO until Pia joins her position
Pia Renaudin has over 20 years of leadership experience from international sales and marketing roles at companies such as AstraZeneca and Gilead Sciences, and is today the General Manager Nordics at Stryker, one of the world's largest medical device companies. Pia holds an MBA from the Gothenburg University and a degree from INSEAD.
"It is with great excitement and enthusiasm that the Board today announces that Pia Renaudin has accepted the role as CEO of Senzime. Pia has led some of the most successful international product launches in the Nordic Life Science industry and, with her impressive track record and well-documented experience in international sales and leadership, we look forward to continue the development of Senzime in becoming a world leader in patient monitoring,” says Philip Siberg, Senzime Chairman of the Board.
"At the same time, the Board wishes to thank Lena Söderström for her leadership and accomplishments as CEO of Senzime. Under Lena's leadership, Senzime has evolved from a small research company into an expanding medical device development company that now has several CE-approved products and distribution agreements in over 20 countries around the world. A new chapter commences for Senzime and Pia will be instrumental in creating value for all stakeholders.” comments Philip Siberg.
Pia Renaudin will start her new leadership position as CEO in the first quarter of 2019. Until that time, Catrin Molund, a current member of Senzime's management team and Director of Marketing & Business Development, will be the Acting CEO. Catrin has over 17 years of experience in the Life Science sector with companies such as Orexo, Phadia, Amersham Biosciences and Pyrosequencing.
For further information, please contact:
Philip Siberg, Chairman of the Board
Tel +46 70 7906734, e-mail: email@example.com
TO THE EDITORS
Senzime develops unique patient-oriented monitoring systems that make it possible to assess patients' biochemical and physiological processes before, during and after surgery. The portfolio of technologies includes bedside systems that enable automated and continuous monitoring of life-critical substances such as glucose and lactate in both blood and tissues, as well as systems to monitor patients’ neuromuscular function perioperatively and in the intensive care medicine setting. The solutions are designed to ensure maximum patient benefit, reduce complications associated with surgery and anesthesia, and decrease health care costs. Senzime operates in growing markets that in Europe and the United States are valued in excess of SEK 10 billion. The company's shares are listed on Nasdaq First North (ticker SEZI). FNCA is Certified Adviser for Senzime. www.senzime.com
This information is insider information that Senzime AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the agency of the contact person set out above, on November 19, 2018.